Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2015, Article ID 464969, 11 pages
http://dx.doi.org/10.1155/2015/464969
Research Article

Urinary Metabolite Profiling Offers Potential for Differentiation of Liver-Kidney Yin Deficiency and Dampness-Heat Internal Smoldering Syndromes in Posthepatitis B Cirrhosis Patients

1E-Institute of Shanghai Municipal Education Committee, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
2Key Laboratory of Liver and Kidney Diseases, Ministry of Education, Institute of Liver Diseases, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
3University of Hawaii Cancer Center, Honolulu, HI 96813, USA
4Key Laboratory of Systems Biomedicine, Ministry of Education, Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai 200240, China
5Center for Chinese Medical Therapy and Systems Biology, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
6Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology, Ministry of Education, Department of Chemistry, Tsinghua University, Beijing 100083, China
7School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100102, China

Received 23 June 2014; Accepted 29 July 2014

Academic Editor: Wei Jia

Copyright © 2015 Xiaoning Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Schuppan and N. H. Afdhal, “Liver cirrhosis,” The Lancet, vol. 371, no. 9615, pp. 838–851, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. G. Garcia-Tsao, S. Friedman, J. Iredale, and M. Pinzani, “Now there are many (stages) where before there was one: in search of a pathophysiological classification of cirrhosis,” Hepatology, vol. 51, no. 4, pp. 1445–1449, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. R. Testa, U. Valente, D. Risso et al., “Can the MEGX test and serum bile acids improve the prognostic ability of Child-Pugh's score in liver cirrhosis?” European Journal of Gastroenterology and Hepatology, vol. 11, no. 5, pp. 559–563, 1999. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Oellerich, M. Burdelski, H.-U. Lautz et al., “Assessment of pretransplant prognosis in patients with cirrhosis,” Transplantation, vol. 51, no. 4, pp. 801–806, 1991. View at Publisher · View at Google Scholar · View at Scopus
  5. A. A. Bravo, S. G. Sheth, and S. Chopra, “Liver biopsy,” New England Journal of Medicine, vol. 344, no. 7, pp. 495–500, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. D. C. Rockey, S. H. Caldwell, Z. D. Goodman, R. C. Nelson, and A. D. Smith, “Liver biopsy,” Hepatology, vol. 49, no. 3, pp. 1017–1044, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. M. Sebagh, D. Samuel, T. M. Antonini et al., “Twenty-year protocol liver biopsies: invasive but useful for the management of liver recipients,” Journal of Hepatology, vol. 56, no. 4, pp. 840–847, 2012. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. A. Szymczak, K. Simon, M. Inglot, and A. Gladysz, “Safety and effectiveness of blind percutaneous liver biopsy: analysis of 1412 procedures,” Hepatitis Monthly, vol. 12, no. 1, pp. 32–37, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. L. Castera and M. Pinzani, “Non-invasive assessment of liver fi brosis: are we ready?” The Lancet, vol. 375, no. 9724, pp. 1419–1420, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Sebastiani, K. Gkouvatsos, and M. Plebani, “Non-invasive assessment of liver fibrosis: it is time for laboratory medicine,” Clinical Chemistry and Laboratory Medicine, vol. 49, no. 1, pp. 13–32, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. Y.-F. Liaw, J.-H. Kao, T. Piratvisuth et al., “Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update,” Hepatology International, vol. 6, no. 3, pp. 531–561, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Yoshioka and S. Hashimoto, “Can non-invasive assessment of liver fibrosis replace liver biopsy?” Hepatology Research, vol. 42, no. 3, pp. 233–240, 2012. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. C. G. Child and J. G. Turcotte, “Surgery and portal hypertension,” Major problems in clinical surgery, vol. 1, pp. 1–85, 1964. View at Google Scholar · View at Scopus
  14. R. N. H. Pugh, I. M. Murray Lyon, and J. L. Dawson, “Transection of the oesophagus for bleeding oesophageal varices,” The British Journal of Surgery, vol. 60, no. 8, pp. 646–649, 1973. View at Publisher · View at Google Scholar · View at Scopus
  15. D. L. Kasper, E. Braunwald, A. S. Fauci, S. L. Hauser, and D. L. Longo, Harrison's Principles of Internal Medicine, McGRaw-Hill, New York, NY, USA, 16th edition, 2005.
  16. D. Benedeto-Stojanov, A. Nagorni, G. Bjelaković, D. Stojanov, B. Mladenović, and N. Djenić, “The Model for the End-Stage Liver Disease and Child-Pugh score in predicting prognosis in patients with liver cirrhosis and esophageal variceal bleeding,” Vojnosanitetski Pregled, vol. 66, no. 9, pp. 724–728, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. J. L. Tang, B. Y. Liu, and K. W. Ma, “Traditional Chinese medicine,” The Lancet, vol. 372, no. 9654, pp. 1938–1940, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. Q. Zhang, P. Liu, H. F. Cheng et al., “Clinical investigation on characteristics of traditional Chinese medical syndrome of hepatocirrhosis,” Journal of Chinese Integrative Medicine, vol. 1, no. 2, pp. 108–112, 2003. View at Google Scholar · View at Scopus
  19. Q. Zhang, W. T. Zhang, J. J. Wei, X. B. Wang, and P. Liu, “Combined use of factor analysis and cluster analysis in classification of traditional Chinese medical syndromes in patients with posthepatitic cirrhosis,” Journal of Chinese Integrative Medicine, vol. 3, no. 1, pp. 14–18, 2005. View at Google Scholar · View at Scopus
  20. Q. Zhang, P. Liu, and H. W. Zhang, “Study on the patterns of TCM syndrome differentiation of 900 patients with posthepatitic cirrhosis,” Zhongguo Zhong Xi Yi Jie He Za Zhi, vol. 26, no. 8, pp. 694–697, 2006. View at Google Scholar
  21. WHO Regional Office for the Western Pacific, WHO International Standard Terminologies on Traditional Medicine in the Western Pacific Region. : World Health Organization, Geneva, Switzerland, 356, 2007.
  22. Z. Hong-ping, “Clinical study of liver cirrhosis treated by integrated traditional Chinese and western medicine,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 21, no. 4, pp. 199–201, 2013. View at Google Scholar
  23. G. Lan-shu and G. Gui-ying, “Clinical observation of triple therapy in integrative chinese and western medicine in treatment of 3266 cases of ascites due to cirrhosis,” World Journal of Integrated Traditional and Western Medicine, vol. 4, no. 7, pp. 523–525, 2009. View at Google Scholar
  24. L. Jian, X. Li-kui, D. Xin et al., “Systematic review of therapeutic effects of traditional chinese medicine on post hepatitic cirrhosis at early stage,” Acta Universitatis Traditionis Medicalis Sinensis Pharmacologiaeque Shanghai, vol. 23, no. 1, pp. 20–23, 2009. View at Google Scholar
  25. Speciality Committee of Digestive Diseases; Chinese Association of Integrative Medicine, “Consensus on the diagnosis and treatment of liver cirrhosis in integrative medicine practice,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 19, no. 4, pp. 277–279, 2011. View at Google Scholar
  26. J. K. Nicholson, J. C. Lindon, and E. Holmes, “'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data,” Xenobiotica, vol. 29, no. 11, pp. 1181–1189, 1999. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. N. J. Waters, C. J. Waterfield, R. D. Farrant, E. Holmes, and J. K. Nicholson, “Metabonomic deconvolution of embedded toxicity: application to thioacetamide hepato- and nephrotoxicity,” Chemical Research in Toxicology, vol. 18, no. 4, pp. 639–654, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. R. Goodacre, “Metabolomics of a superorganism,” Journal of Nutrition, vol. 137, no. 1 supplement, pp. 259S–266S, 2007. View at Google Scholar · View at Scopus
  29. W. M. Claudino, A. Quattrone, L. Biganzoli, M. Pestrin, I. Bertini, and A. Di Leo, “Metabolomics: available results, current research projects in breast cancer, and future applications,” Journal of Clinical Oncology, vol. 25, no. 19, pp. 2840–2846, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. W. R. Wikoff, J. A. Gangoiti, B. A. Barshop, and G. Siuzdak, “Metabolomics identifies perturbations in human disorders of propionate metabolism,” Clinical Chemistry, vol. 53, no. 12, pp. 2169–2176, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. W. O. Opii, G. Joshi, E. Head et al., “Proteomic identification of brain proteins in the canine model of human aging following a long-term treatment with antioxidants and a program of behavioral enrichment: relevance to Alzheimer's disease,” Neurobiology of Aging, vol. 29, no. 1, pp. 51–70, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. Y. Qiu, G. Cai, M. Su et al., “Urinary metabonomic study on colorectal cancer,” Journal of Proteome Research, vol. 9, no. 3, pp. 1627–1634, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. T. Chen, G. Xie, X. Wang et al., “Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma,” Molecular & Cellular Proteomics, vol. 10, no. 7, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. Y. Cheng, G. Xie, T. Chen et al., “Distinct urinary metabolic profile of human colorectal cancer,” Journal of Proteome Research, vol. 11, no. 2, pp. 1354–1363, 2012. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. X. Wang, X. Wang, G. Xie et al., “Urinary metabolite variation is associated with pathological progression of the post-hepatitis B cirrhosis patients,” Journal of Proteome Research, vol. 11, no. 7, pp. 3838–3847, 2012. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. C. M. A. Chinese Society of Hepatology and C. M. A. Chinese Society of Infectious Diseases, “Guideline on prevention and treatment of chronic hepatitis B in China (2005),” Chinese Medical Journal, vol. 120, no. 24, pp. 2159–2173, 2005. View at Google Scholar
  37. Y. Qiu, M. Su, Y. Liu et al., “Application of ethyl chloroformate derivatization for gas chromatography-mass spectrometry based metabonomic profiling,” Analytica Chimica Acta, vol. 583, no. 2, pp. 277–283, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. H. Zhang, X. Chen, P. Hu et al., “Metabolomic profiling of rat serum associated with isoproterenol-induced myocardial infarction using ultra-performance liquid chromatography/time-of-flight mass spectrometry and multivariate analysis,” Talanta, vol. 79, no. 2, pp. 254–259, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. S. W. Schalm, “The diagnosis of cirrhosis: clinical relevance and methodology,” Journal of Hepatology, vol. 27, no. 6, pp. 1118–1119, 1997. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Colli, M. Fraquelli, M. Andreoletti, B. Marino, E. Zuccoli, and D. Conte, “Severe liver fibrosis or cirrhosis: accuracy of US for detection—analysis of 300 cases,” Radiology, vol. 227, no. 1, pp. 89–94, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. A. Zipprich, G. Garcia-Tsao, S. Rogowski, W. E. Fleig, T. Seufferlein, and M. M. Dollinger, “Prognostic indicators of survival in patients with compensated and decompensated cirrhosis,” Liver International, vol. 32, no. 9, pp. 1407–1414, 2012. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. G. D'amico, A. Morabito, L. Pagliaro, and E. Marubini, “Survival and prognostic indicators in compensated and decompensated cirrhosis,” Digestive Diseases and Sciences, vol. 31, no. 5, pp. 468–475, 1986. View at Publisher · View at Google Scholar · View at Scopus
  43. A. S. F. Lok and B. J. McMahon, “Chronic hepatitis B,” Hepatology, vol. 45, no. 2, pp. 507–539, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. Y. Arakawa, M. Moriyama, and Y. Arakawa, “Liver cirrhosis and metabolism (sugar, protein, fat and trace elements),” Hepatology Research, vol. 30, pp. S46–S58, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. M. Kato and H. Moriwaki, “Metabolic disorders in patients with liver cirrhosis,” Hepatology Research, vol. 30, pp. S59–S62, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  46. J. K. Nicholson, E. Holmes, J. Kinross et al., “Host-gut microbiota metabolic interactions,” Science, vol. 336, no. 6086, pp. 1262–1267, 2012. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. J. N. Thompson, J. Cohen, J. I. Blenkharn, J. S. McConnell, J. Barr, and L. H. Blumgart, “A randomized clinical trial of oral ursodeoxycholic acid in obstructive jaundice,” British Journal of Surgery, vol. 73, no. 8, pp. 634–636, 1986. View at Publisher · View at Google Scholar · View at Scopus
  48. E. M. M. Kuiper, B. E. Hansen, W. Lesterhuis et al., “The long-term effect of ursodeoxycholic acid on laboratory liver parameters in biochemically non-advanced primary biliary cirrhosis,” Clinics and Research in Hepatology and Gastroenterology, vol. 35, no. 1, pp. 29–33, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  49. C. Tiribelli and J. D. Ostrow, “Intestinal flora and bilirubin,” Journal of Hepatology, vol. 42, no. 2, pp. 170–172, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  50. E. Seki and D. A. Brenner, “Toll-like receptors and adaptor molecules in liver disease: update,” Hepatology, vol. 48, no. 1, pp. 322–335, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  51. I. N. Crispe, “The liver as a lymphoid organ,” Annual Review of Immunology, vol. 27, pp. 147–163, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  52. J. P. Pradere, J. S. Troeger, D. H. Dapito, A. A. Mencin, and R. F. Schwabe, “Toll-like receptor 4 and hepatic fibrogenesis,” Seminars in Liver Disease, vol. 30, no. 3, pp. 232–244, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  53. C. C. Chan, S. J. Hwang, F. Y. Lee et al., “Prognostic value of plasma endotoxin levels in patients with cirrhosis,” Scandinavian Journal of Gastroenterology, vol. 32, no. 9, pp. 942–946, 1997. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  54. R.-S. Lin, F.-Y. Lee, S.-D. Lee et al., “Endotoxemia in patients with chronic liver diseases: relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation,” Journal of Hepatology, vol. 22, no. 2, pp. 165–172, 1995. View at Publisher · View at Google Scholar · View at Scopus
  55. G. Y. Chen and G. Nuñez, “Sterile inflammation: sensing and reacting to damage,” Nature Reviews Immunology, vol. 10, no. 12, pp. 826–837, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. T. A. Miettinen, “Lipid absorption, bile acids, and cholesterol metabolism in patients with chronic liver disease,” Gut, vol. 13, no. 9, pp. 682–689, 1972. View at Publisher · View at Google Scholar · View at Scopus
  57. J. Y. Sung, E. A. Shaffer, and J. W. Costerton, “Antibacterial activity of bile salts against common biliary pathogens: effects of hydrophobicity of the molecule and in the presence of phospholipids,” Digestive Diseases and Sciences, vol. 38, no. 11, pp. 2104–2112, 1993. View at Publisher · View at Google Scholar · View at Scopus
  58. Y. Chen, F. Yang, H. Lu et al., “Characterization of fecal microbial communities in patients with liver cirrhosis,” Hepatology, vol. 54, no. 2, pp. 562–572, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  59. H. Lu, Z. Wu, W. Xu, J. Yang, and Y. Chen, “Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection. Intestinal microbiota of HBV cirrhotic patients,” Microbial Ecology, vol. 61, no. 3, pp. 693–703, 2011. View at Google Scholar
  60. W. Zhang, Y. Gu, Y. Chen et al., “Intestinal flora imbalance results in altered bacterial translocation and liver function in rats with experimental cirrhosis,” European Journal of Gastroenterology and Hepatology, vol. 22, no. 12, pp. 1481–1486, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  61. L. Li, Z. Wu, W. Ma, Y. Yu, and Y. Chen, “Changes in intestinal microflora in patients with chronic severe hepatitis,” Chinese Medical Journal, vol. 114, no. 8, pp. 869–872, 2001. View at Google Scholar · View at Scopus
  62. C. Hong-xin, General Introduction to TCM Theory, Science Press, Beijing, China, 2011.